The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Mechanisms of resistance to 5-aza-2′-deoxycytidine in human cancer cell lines
Open accessAbstract
5-aza-2′-deoxycytidine (DAC) is approved for the treatment of myelodysplastic syndromes, but resistance to this agent is common. In search for mechanisms of resistance, we measured the half maximal (50%) inhibitory concentration (IC50) of DAC and found it differed 1000-fold among a panel of cancer cell lines. The IC50 was correlated with the doses of DAC that induced the most hypomethylation of long interspersed nuclear elements (LINE; R = 0.94, P < .001), but not with LINE methylation or DNA methyltransferase 1 (DNMT1), 3a, and 3b expression at baseline. Sensitivity to DAC showed a low correlation (R = 0.44, P = .11) to that of 5-azacytidine (AZA), but a good correlation to that of cytarabine (Ara-C; R = 0.89, P < .001). The 5 cell lines most resistant to DAC had a combination of low dCK, hENT1, and 2 transporters, and high cytosine deaminase. In an HL60 clone, resistance to DAC could be rapidly induced by drug exposure and was related to a switch from heterozygous to homozygous mutation of DCK. Transfection of wild-type DCK restored DAC sensitivity. DAC induced DNA breaks as evidenced by H2AX phosphorylation and increased homologous recombination rates by 7- to 10-fold. These results suggest that in vitro resistance to DAC can be explained by insufficient incorporation into DNA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
Genetic instabilities in human cancers
Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1998) · Nature · doi:10.1038/25292 · Cited by 4,168
Pharmacology of 5-Aza-2′-deoxycytidine (decitabine)
Momparler, R. L. (2005) · Seminars in Hematology · doi:10.1053/j.seminhematol.2005.05.002 · Cited by 231
Cited by
Issa, J.-P. J., & Kantarjian, H. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2783 · Cited by 446
Self-citationTaby, R., & Issa, J.-P. J. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20085 · Cited by 407
Self-citationA Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines
Hollenbach, P. W., Nguyen, A. N., Brady, H., Williams, M., Ning, Y., Richard, N., Krushel, L., Aukerman, S. L., Heise, C., & MacBeth, K. J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009001 · Cited by 362
Targeting DNA methylation for epigenetic therapy
Yang, X., Lay, F., Han, H., & Jones, P. A. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.08.001 · Cited by 326
Cancer epigenetics: linking basic biology to clinical medicine
Tsai, H.-C., & Baylin, S. B. (2011) · Cell Research · doi:10.1038/cr.2011.24 · Cited by 297
Metadata
- Authors
- Qin, T., Jelinek, J., Si, J., Shu, J., & Issa, J.-P. J.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2009-01-15
- Volume
- 113
- Issue
- 3
- Pages
- 659-667
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2068296418
- Cited by
- 237
- References
- 3
- FWCI
- 5.58
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mechanisms of resistance to 5-aza-2′-deoxycytidine in human cancer cell lines. https://app.cochat.ai/papers/10.1182/blood-2008-02-140038
- The paper
- Qin, T., Jelinek, J., Si, J., Shu, J., & Issa, J.-P. J. (2009). Mechanisms of resistance to 5-aza-2′-deoxycytidine in human cancer cell lines. Blood. https://doi.org/10.1182/blood-2008-02-140038
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.